Abstract:Positive allosteric modulators of centrally expressed nicotinic acetylcholine receptors have therapeutic potentials in areas of cognition, motor function and reward. Several chemical classes of allosteric modulators that are selective for α7 nicotinic receptors have been characterised, but potentiators for the most widely expressed α4β2 nicotinic receptor subtype are few and less defined, owing probably to the difficulty to achieve selectivity over other heteromeric receptor subtypes. 2087101 (2-amino-5-keto)thiazole) is a potent potentiator of both α7 and α4β2 receptors and it has selectivity against the α3β4 subtype, which may be responsible for the undesirable peripheral side effects. To further characterise its ability to differentiate between native nicotinic receptors, we examined the effects of 2087101 on α7, α4β2* and α3β4* receptor-mediated responses in the rat brain in electrophysiological and neurochemical experiments. 2087101 significantly potentiated agonist-induced, α7 and non-α7 receptor-mediated, GABAergic postsynaptic currents in cultured hippocampal neurones, but not the nicotine-stimulated [3H]noradrenaline release from hippocampal slices, which was primarily mediated by α3β4* receptors, confirming its selectivity for α7 and α4β2* receptors in native systems. 2087101 also significantly enhanced nicotine-stimulated firing increase in dopamine neurones of the ventral tegmental area, an effect that was dihydro-β-erythroidine-sensitive and thereby mediated by α4β2* nicotinic receptors. 2087101 can therefore enhance native nicotinic activities mediated by α7 and α4β2*, but not α3β4* receptors, showing its unique ability to discriminate between native heteromeric nicotinic receptor subtypes and its therapeutic potential for treating brain disorders by concurrent modulation of both α7 and α4β2* nicotinic receptors.

Agonist-selective activation of individual G-proteins by muscarinic receptors

Single Hormone or Synthetic Agonist Induces G S /G I Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths

Importance of receptor expression in the classification of novel ligands at the M2 muscarinic acetylcholine receptor

Design of allosteric modulators that change GPCR G protein subtype selectivity

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Positive allosteric modulation of a GPCR ternary complex

Muscarinic Receptors and Related Selective Drugs: Research Advances

Design, Synthesis, and Biological Evaluation of 4,4’-Difluorobenzhydrol Carbamates as Selective M1 Antagonists

Muscarinic Acetylcholine Receptor Modulators Derived from Natural Toxins and Diverse Interaction Modes

Structural and dynamic insights into supra-physiological activation and allosteric modulation of a muscarinic acetylcholine receptor

Structure and dynamics determine G protein coupling specificity at a class A GPCR

Characterization of Gα and Gα activation by catechol and non-catechol dopamine D1 receptor agonists

Functional selectivity and dualsteric/bitopic GPCR targeting

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

The Subtype-Selective Nicotinic Acetylcholine Receptor Positive Allosteric Potentiator 2087101 Differentially Facilitates Neurotransmission in the Brain.

Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression

Fine-tuning activation specificity of G-protein-coupled receptors via automated path searching

Receptor selectivity from minimal backbone modification of a polypeptide agonist

Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation

New potent muscarinic receptor ligands bearing the 1,4‐dioxane nucleus: Investigation on the nature of the substituent in position 2